Cartherics and TiCARos have recently joined forces in a collaboration to develop CAR-NK cell products for the treatment of cancer. The goal of this partnership is to improve the efficacy of cancer therapies by combining TiCARos’ CLIP-CAR technology with Cartherics’ allogeneic NK cell platform.

TiCARos specializes in the development of CAR-T cell products for the treatment of solid and blood cancers using its unique CLIP-CAR approach. This approach modifies the CAR structure to stabilize the immune synapse between immune cells and target tumor cells, leading to improved efficacy in models. Meanwhile, Cartherics has developed an allogeneic NK cell platform that can be used to generate CAR-NK cells for the treatment of cancer.

The collaboration between these two companies aims to develop a new CAR-NK product that targets tissue factor (TF) for triple-negative breast cancer and other challenging cancers. Each company has nominated a specific tumor antigen for CAR targeting, with Cartherics focusing on TF and TiCARos targeting CD19. The goal of this research collaboration is to accelerate pipeline programs and expand the use of TiCARos’ technology beyond autologous cell therapies.

If the research collaboration yields positive results, Cartherics and TiCARos will negotiate an agreement to develop and commercialize their CAR-NK therapeutic approach. This partnership has the potential to revolutionize cancer treatments by improving their effectiveness and safety, ultimately leading to better outcomes for patients.

By Samantha Johnson

As a dedicated content writer at, I immerse myself in the art of storytelling through words. With a keen eye for detail and a passion for crafting engaging narratives, I strive to captivate our audience with each piece I create. Whether I'm covering breaking news, delving into feature articles, or exploring thought-provoking editorials, my goal remains constant: to inform, entertain, and inspire through the power of writing. Join me on this journalistic journey as we navigate through the ever-evolving media landscape together.

Leave a Reply